259 related articles for article (PubMed ID: 27536067)
1. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.
Pinheiro M; Ribeiro R; Vieira A; Andrade F; Reis S
Drug Des Devel Ther; 2016; 10():2467-75. PubMed ID: 27536067
[TBL] [Abstract][Full Text] [Related]
2. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
[TBL] [Abstract][Full Text] [Related]
3. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
4. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.
Vieira AC; Chaves LL; Pinheiro M; Ferreira D; Sarmento B; Reis S
Int J Nanomedicine; 2016; 11():2601-17. PubMed ID: 27354792
[TBL] [Abstract][Full Text] [Related]
5. Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment.
Vieira AC; Magalhães J; Rocha S; Cardoso MS; Santos SG; Borges M; Pinheiro M; Reis S
Nanomedicine (Lond); 2017 Dec; 12(24):2721-2736. PubMed ID: 29119867
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system.
Zhu L; Chen L; Cao QR; Chen D; Cui J
J Control Release; 2011 Nov; 152 Suppl 1():e190-1. PubMed ID: 22195844
[No Abstract] [Full Text] [Related]
7. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies.
Gaspar DP; Faria V; Gonçalves LM; Taboada P; Remuñán-López C; Almeida AJ
Int J Pharm; 2016 Jan; 497(1-2):199-209. PubMed ID: 26656946
[TBL] [Abstract][Full Text] [Related]
8. Gelatin nanocarriers as potential vectors for effective management of tuberculosis.
Saraogi GK; Gupta P; Gupta UD; Jain NK; Agrawal GP
Int J Pharm; 2010 Jan; 385(1-2):143-9. PubMed ID: 19819315
[TBL] [Abstract][Full Text] [Related]
9. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
10. Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy.
Maretti E; Costantino L; Buttini F; Rustichelli C; Leo E; Truzzi E; Iannuccelli V
Drug Deliv Transl Res; 2019 Feb; 9(1):298-310. PubMed ID: 30484257
[TBL] [Abstract][Full Text] [Related]
11. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
Shete H; Patravale V
Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug.
Ebrahimi HA; Javadzadeh Y; Hamidi M; Barzegar Jalali M
J Pharm Pharmacol; 2016 Apr; 68(4):450-8. PubMed ID: 27114047
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization.
Khan S; Shaharyar M; Fazil M; Baboota S; Ali J
Eur J Pharm Biopharm; 2016 Nov; 108():277-288. PubMed ID: 27449630
[TBL] [Abstract][Full Text] [Related]
14. Lipid Nanocarrier-Mediated Drug Delivery System to Enhance the Oral Bioavailability of Rifabutin.
Nirbhavane P; Vemuri N; Kumar N; Khuller GK
AAPS PharmSciTech; 2017 Apr; 18(3):829-837. PubMed ID: 27350276
[TBL] [Abstract][Full Text] [Related]
15. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
Yang Y; Xie X; Yang Y; Zhang H; Mei X
J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail.
Alam S; Aslam M; Khan A; Imam SS; Aqil M; Sultana Y; Ali A
Drug Deliv; 2016; 23(2):601-9. PubMed ID: 24937378
[TBL] [Abstract][Full Text] [Related]
17. Multiple Lipid Nanoparticles (MLN), a New Generation of Lipid Nanoparticles for Drug Delivery Systems: Lamivudine-MLN Experimental Design.
Cavalcanti SMT; Nunes C; Lima SAC; Soares-Sobrinho JL; Reis S
Pharm Res; 2017 Jun; 34(6):1204-1216. PubMed ID: 28315084
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid.
Ruktanonchai U; Bejrapha P; Sakulkhu U; Opanasopit P; Bunyapraphatsara N; Junyaprasert V; Puttipipatkhachorn S
AAPS PharmSciTech; 2009; 10(1):227-34. PubMed ID: 19280350
[TBL] [Abstract][Full Text] [Related]
19. Topical phenytoin nanostructured lipid carriers: design and development.
Motawea A; Borg T; Abd El-Gawad AEH
Drug Dev Ind Pharm; 2018 Jan; 44(1):144-157. PubMed ID: 28956451
[TBL] [Abstract][Full Text] [Related]
20. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery.
Zoubari G; Staufenbiel S; Volz P; Alexiev U; Bodmeier R
Eur J Pharm Biopharm; 2017 Jan; 110():39-46. PubMed ID: 27810471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
